Sensory-motor axonal multineuropathy during etanercept therapy for rheumatoid arthritis

Sirs,

A 48-year-old woman had a 4-month history of polyarthritides without extra-articular features and particularly without skin lesions or neurologic impairment. Laboratory data showed RF at 203 IU/ml and elevated inflammatory markers while anti-CCP, ANA, ds-DNA, anti-ENA, APA, ANCA, serum complement and immunoglobulin levels were normal. Serology for recent infection was negative. X-rays of the wrists, hands and feet showed juxta-articular osteoporosis. These features were consistent with highly active RA, refractory to treatment including prednisone (12.5 mg/die), NSAIDs and intraarticular injections of triamcinolone-acetonide. To achieve a rapid disease control with a monotherapy, etanercept (25 mg twice a week) without DMARDs was added to prednisone. About 2 months later the patient was in remission, polyarthritides was uncontrolled. In addition she reported a burning sensation in the feet and asymmetric paroxysmal dyesthesia involving the legs. Methotrexate (MTX) was added (15 mg weekly). The patient achieved a reduction of the swollen and tenderness joint count. However, dysesthesia worsened, became chronic and symmetric in the lower limbs and spread asymmetrically in the upper limbs. Furthermore, the patient had developed severe motor distal deficit particularly in the lower limbs. The electromyographic pattern was compatible with a sensory-motor axonal multi-polyneuropathy. RF was raised at 445 IU/ml while serum complement, immunoglobulin levels, anti-CCP, ANA, anti-dsDNA, anti-ENA, APA, ANCA, anti-ganglioside, anti-myelin protein and anti-cerebellum were normal. Anti-PPD, anti-HIV, anti-Borrelia and serological hepatic markers were negative. Investigations for PCR for HSV-1 and HSV-2 DNA, Cytomegalovirus DNA and Epstein-Barr virus DNA on blood were negative. Biopsy specimens were taken from the left sural nerve. Histological analysis showed axonal neuropathy without vascular inflammatory infiltrate (Fig. 1). Etanercept and MTX were discontinued and prednisone was increased (50 mg/die). Moreover, monthly plasma exchange followed by intravenous cyclophosphamide therapy (500mg/m²) and monthly therapy with high doses of intravenous Ig (400 mg/kg/die for 3 days) were given. Within 2 months the patient achieved a progressive improvement in the neurological features. Follow-up investigations 3 months later showed further improvement in the neuropathy. Our patient had a sensory-motor axonal multi-neuropathy suggesting vasculitic pathogenesis although histological analysis of nerve sample was characterised by absence of vascular inflammatory infiltrate. Some histological changes as pronounced monofacial myelinated fiber loss, more evident in centrofascicular area, typically are seen in ischemic damage. On the contrary, the electromyographic and histological patterns exclude a demyelinating neuropathy (Guillain-Barré syndrome, etc.). We cannot definitely exclude the development of rheumatoid vasculitis-associated multineuropathy refractory to etanercept and MTX therapy. However, our patient did not have characteristics predisposing her to the development of rheumatoid vasculitis, particularly nodularity and skin lesions. On the contrary, the temporal relationship between the onset of neuropathy and the initiation of etanercept therapy suggest that the drug may have contributed to trigger the neurologic disease. While some reports have suggested that inhibition of TNF-α may be effective in rheumatoid vasculitis-associated mononeuropathy (1-2), others have suggested that anti-TNF-α can induce, in patients with RA, the development of vasculitis (3-6) and particularly necrotizing vasculitis-associated sensory and motor neuropathy (7-8) or the progression of rheumatoid vasculitis-associated mononeuropathies (8). There are a number of possible drug-related mechanisms that may be involved, immunopathogenic mechanism or infectious complications. In our case the onset of multineuropathy was not associated with the production of autoantibodies and there were no signs of neurotoxic infective complications. Future studies should help to define the role of anti-TNF-α in the development of vasculitis and, particularly, in the development of axonal multineuropathy. Undoubtedly, an inflammatory axonal neuropathy may develop in patients with RA treated with anti-TNF-α. This possibility demand careful neurological monitoring in such patients and prompts us to suggest, in agreement with Richette (9) and Guillemin (10), the use of anti-TNF-α only in patients with vasculitis refractory to sirolimus and immunosuppressants agents.

R. De STEFANO, MD
E. FRATI, Researcher
N. VOLPI, Researcher
M. GALEAZZI, Professor

“U.O.C. of Rheumatology, Department of Specialistic Medicine, Azienda Ospedaliero Universitaria Senese, Siena; 2Department of Clinical Medicine and Immunological Sciences, Institute of Rheumatology, Department of Biomedical Sciences, Institute of Anatomy and Histology, University of Siena, Siena, Italy.

The work should be attributed to the Department of Clinical Medicine and Immunological Sciences, Institute of Rheumatology, University of Siena, Siena, Italy.

Author correspondence and reprint requests to: Renato Di Stefano, viale Bruccii 1, Siena, Italy.

E-mail: donamara2006@libero.it

Competing interests: none declared.

References